A new Phase 3 clinical trial involving insulin degludec was registered as of November 3, 2026. The study, titled "A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin," is listed under identifier NCT07913061.
According to the registration, the trial is designed to compare SHR-3167 against insulin degludec in adults with type 2 diabetes who are currently being treated with basal insulin. The trial status is listed as not yet recruiting, meaning participant enrollment has not yet begun as of the registration date.
The trial is designated as Phase 3, indicating it is intended to be a later-stage study in the overall development process. No results, outcomes, or additional design details have been posted at this time. As the study has not yet begun recruiting, no further information about enrollment timelines, participant numbers, or trial sites is currently available.
Readers interested in further developments regarding this trial can monitor the registration for updates on recruitment status and eventual results. For additional background on insulin degludec and its approved uses, readers can consult the compound overview.